Lithuania · 
Who invested in Sentante?
Sentante's investors include EIC Accelerator, MedTech Innovator and Practica Capital.
Lithuania · Seed startup
Who invested in Sentante
Funding summaryUpdated 26 Oct 2026
$6.6Mraised across 1 round since 2023, from 1 source
- Latest round
- Seed, $6.6MDec 2023
- Investors
- 3
The rounds
- Dec 2023
Founders and team
From Sentante's own website: 10 on the team.
- Edvardas SatkauskasChief Executive Officer
- Dr. Evaldas KalvaitisChief Supply Chain Officer
- Dr. Tomas BaltrūnasChief Medical Officer
- Simona Kesminaitė-MingėlėChief Accountant
- Vilius DambrauskasChief Technology Officer
- Daumantas BarčasHead of Production
- Dr. Leona DamalakienėHead of Clinical Affairs
- Julian RieckVP Peripheral Europe
- Paulius DambrauskasHead of Quality Assurance and Regulatory Affairs
- Ugnė GurskėHead of Human Resources
AdvisersCristopher PrenticeDr. David S. LiebeskindDr. Gary AnselDr. Giovanni TorselloDr. Michael LichtenbergDr. Michael R. JaffDr. Peter SchneiderDr. Ricardo A. HanelMatt Lemay
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists Sentante as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about Sentante
How much has Sentante raised?
Sentante has raised $6.6M across 1 round since 2023.
When did Sentante last raise?
Sentante's most recent round was a Seed of $6.6M in Dec 2023.
What was Sentante's biggest round?
Its most recent round, $6.6M in Dec 2023, is also its largest on record.
Who backed Sentante first?
Sentante's first round on record, in Dec 2023, was backed by EIC Accelerator, MedTech Innovator and Practica Capital.
What stage is Sentante at?
Sentante's latest named round is a Seed, in Dec 2023.
Where is Sentante based?
Sentante is based in Lithuania.
Companies like Sentante
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.